Search clinical trials for: Enasidenib Mesylate

Total 1679 results

Jewish General Hospital
Novartis Pharmaceuticals

Terminated

Dose Escalation Study of Gleevec and Chlorambucil in Previously Treated Chronic Lymphocytic Leukemia Patients (GL-CLB-001)

Chronic Lymphocytic Leukemia

Canada
National Cancer Institute (NCI)

Terminated

Imatinib Mesylate in Treating Patients With Progressive, Refractory, or Recurrent Stage II or Stage III Testicular or Ovarian Cancer

Testicular Seminoma | Recurrent Ovarian Germ Cell Tumor | Stage II Ovarian Germ Cell Tumor | Stage III Ovarian Germ Cell Tumor | Ovarian Dysgerminoma | Recurrent Malignant Testicular Germ Cell Tumor | Stage II Malignant Testicular Germ Cell Tumor | Stage III Malignant Testicular Germ Cell Tumor

United States
xuna
Nanfang Hospital of Southern Medical University; Sun Yat-Sen Memorial Hospital... and other collaborators

Withdrawn

Prophylactic HQP1351 Therapy Post-transplants on Leukemia After Allo-HSCT (Case-Only)

Prophylactic HQP1351 Therapy | Third Generation TKI

China
H. Lee Moffitt Cancer Center and Research Institute
Eisai Inc.

Completed

A Phase I Dose Escalation Study of Eribulin Plus Weekly Carboplatin for Metastatic Breast Patients

Breast Cancer

United States
Synta Pharmaceuticals Corp.

Completed

Study of STA-5326 Mesylate in Patients With Moderate to Severe Crohn's Disease

Crohn's Disease

United States, Canada
Elevar Therapeutics

Terminated

A Study of Rivoceranib and Trifluridine/Tipiracil for Metastatic Colorectal Cancer (mCRC)

Metastatic Colorectal Cancer

United States
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

Multicenter Study of Rasagiline in Parkinson's Disease Patients Using Levodopa and Experiencing Motor Fluctuations

Parkinson's Disease

United States
Taivex Therapeutics Corporation

Terminated

Safety and Tolerability Study for T-1101 (Tosylate) to Treat Advanced Refractory Solid Tumors

Advanced Refractory Solid Tumors

Taiwan
Shire

Completed

Safety, Tolerability, Pharmacokinetic, and Efficacy Study of SPD489 in Preschool Children With Attention-deficit/Hyperactivity Disorder

Attention Deficit Hyperactivity Disorder (ADHD)

United States
MedSIR
Menarini Group

Recruiting

PIK3CA/PTEN-altered Advanced Breast Cancer Treated With MEN1611 Monotherapy or in Combination With Eribulin (SABINA)

Breast Cancer | Advanced Breast Cancer | Metastatic Breast Cancer

Spain
Bausch & Lomb Incorporated

Completed

Safety, Pharmacokinetics, and Efficacy of Bepotastine Besilate Nasal Product After Ragweed Pollen Exposure in an Environmental Chamber

Seasonal Allergic Rhinitis

United States
Taivex Therapeutics Corporation

Active, not recruiting

Safety and Tolerability Study for T-1101 (Tosylate) Capsules to Treat Advanced Refractory Solid Tumors

Advanced Refractory Solid Tumors

Taiwan
Taivex Therapeutics Corporation

Completed

An Extension Study for T-1101 (Tosylate) to Treat Advanced Refractory Solid Tumors

Advanced Refractory Solid Tumors

Taiwan
University of Washington
National Cancer Institute (NCI)

Completed

Eribulin Mesylate in Treating Patients With Previously Treated Metastatic Breast Cancer

Stage IV Breast Cancer | Recurrent Breast Carcinoma

United States
New Mexico Cancer Care Alliance
Novartis; Fred Hutchinson Cancer Center

Completed

Study of Gleevec and Weekly Paclitaxel in Patients Aged 70 or Older With Advanced Non-small Cell Lung Cancer (6137p)

Non-small Cell Lung Cancer

United States
Abbott
Quintiles, Inc.; Synexus; author! et al. BV

Completed

Comparison of the Effect of Eprosartan and Eprosartan Mesylate on Blood Pressure in Essential Hypertension

Essential Hypertension

Germany, Russian Federation, United Kingdom
Synta Pharmaceuticals Corp.
National Institute of Allergy and Infectious Diseases (NIAID); National Institutes...

Completed

Study of STA-5326 Mesylate in Patients With Moderate to Severe Crohn's Disease

Crohn's Disease

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Nilotinib and Imatinib Mesylate After Donor Stem Cell Transplant in Treating Patients With ALL or CML

Accelerated Phase Chronic Myelogenous Leukemia | Adult Acute Lymphoblastic Leukemia in Remission | Childhood Acute Lymphoblastic Leukemia in Remission | Childhood Chronic Myelogenous Leukemia | Chronic Phase Chronic Myelogenous Leukemia | Recurrent Adult Acute Lymphoblastic Leukemia | Recurrent... and other conditions

United States
Duke University
National Cancer Institute (NCI); Novartis Pharmaceuticals

Completed

Imatinib Mesylate and Hydroxyurea in Treating Patients With Recurrent or Progressive Meningioma

Glioblastoma | Gliosarcoma

United States
Dong-A ST Co., Ltd.

Completed

A Clinical Trial to Compare the Pharmacokinetics of Imatinib Mesylate Tablet 400mg (1 Tablet) and Glivec Film-coated Tablet 100mg (4 Tablets)(Phase I)

Chronic Myeloid Leukemia | Gastrointestinal Stromal Tumor

Korea, Republic of
Novartis Pharmaceuticals

Completed

Study of Imatinib Mesylate in Combination With Hydroxyurea Versus Hydroxyurea Alone as an Oral Therapy in Patients With Temozolomide Resistant Progressive Glioblastoma

Astrocytoma | Glioblastoma Multiforme

Germany
Samsung Bioepis Co., Ltd.

Completed

A Study to Compare SB17 (Proposed Ustekinumab Biosimilar) to Stelara® in Subject With Moderate to Severe Plaque Psoriasis

Psoriasis | Moderate to Severe Plaque Psoriasis

Czechia, Estonia, Hungary, Korea, Republic of, Latvia, Lithuania, Poland, Ukraine
National Cancer Institute (NCI)

Completed

Eribulin Mesylate in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy

Recurrent Prostate Cancer | Adenocarcinoma of the Prostate | Stage IV Prostate Cancer | Hormone-refractory Prostate Cancer

United States
Hospices Civils de Lyon

Unknown

AFR10 - Combination Therapy of Imatinib Mesylate (IM) + Alpha-2A Interferon for Chronic Phase CML Patients Resistant or Refractory to IM Used as Single Therapy for at Least One Year

Chronic Myeloid Leukemia

France
PIQUR Therapeutics AG
Hospital Universitari Vall d'Hebron Research Institute; Institut Català d'Oncologia and other collaborators

Completed

PQR309 and Eribulin in Metastatic HER2 Negative and Triple-negative Breast Cancer (PIQHASSO)

Metastatic Breast Cancer

Spain, United Kingdom
National Cancer Institute (NCI)

Completed

Eribulin Mesylate in Treating Patients With Recurrent Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer

Fallopian Tube Cancer | Primary Peritoneal Cavity Cancer | Recurrent Ovarian Epithelial Cancer

United States
Synta Pharmaceuticals Corp.

Completed

A Randomized, Double-blind, Placebo-controlled Clinical Study of the Oral IL-12/23 Inhibitor, STA-5326 Mesylate, Administered to Patients With Rheumatoid Arthritis to Determine Safety, Tolerability, Pharmacokinetic and Synovial Tissue Outcomes

Active, Moderate to Severe Rheumatoid Arthritis

Netherlands
Daiichi Sankyo Co., Ltd.

Active, not recruiting

Valemetostat Tosylate (DS-3201b) Phase 2 Study in Relapsed or Refractory Adult T-cell Leukemia/Lymphoma

Adult T-cell Leukemia/Lymphoma

Japan
New York State Psychiatric Institute
Intra-Cellular Therapies, Inc.

Terminated

ITI-007 (Lumateperone Tosylate) for Schizophrenia

Schizophrenia

United States
City of Hope Medical Center
National Cancer Institute (NCI); Eisai Inc.

Completed

Neuropharmacokinetics of Eribulin Mesylate in Treating Patients With Primary or Metastatic Brain Tumors

Primary Brain Tumor | Metastatic Malignant Neoplasm in the Adult Brain

United States
National Cancer Institute (NCI)

Completed

Eribulin Mesylate as Second-Line Therapy for Locally Advanced, Unresectable, or Metastatic Pancreatic Cancer Patients

Pancreatic Cancer | Adenocarcinoma of the Pancreas | Recurrent Pancreatic Cancer | Stage III Pancreatic Cancer | Stage IV Pancreatic Cancer | Stage II Pancreatic Cancer

Canada
National Cancer Institute (NCI)

Completed

E7389 in Treating Patients With Recurrent or Progressive Stage IIIB or Stage IV Non-Small Cell Lung Cancer

Stage IIIB Non-small Cell Lung Cancer | Recurrent Non-small Cell Lung Cancer | Stage IV Non-small Cell Lung Cancer

United States
Eli Lilly and Company

Completed

Treatment of Peripheral Neuropathy in Patients With Diabetes

Diabetes Mellitus | Diabetic Neuropathies

United States, Spain, Australia, Belgium, Canada, Croatia, Denmark, Estonia, Finland, Germany, Hungary, India, Lithuania, Netherlands, United Kingdom
Eli Lilly and Company

Completed

Treatment for Symptomatic Peripheral Neuropathy in Patients With Diabetes

Diabetic Neuropathies | Diabetes Mellitus, Non-Insulin-Dependent | Diabetes Mellitus, Insulin-Dependent

United States, Spain, Hungary, Australia, Belgium, Denmark, Estonia, Germany, Israel
Vitreous -Retina- Macula Consultants of New York
Genentech, Inc.

Withdrawn

Imatinib Mesylate Combined With Intravitreal Ranibizumab in the Treatment of Choroidal Neovascularization Secondary to Age-Related Macular Degeneration

Choroidal Neovascularization

United States
The Lymphoma Academic Research Organisation
Daiichi Sankyo

Active, not recruiting

Study of Valemetostat Tosylate as a Single Agent in Patients With Relapse/Refractory B-cell Lymphoma

Lymphoma, B-Cell

France, Belgium
AI Therapeutics, Inc.

No longer available

An Open-Label, Expanded Access Protocol of LAM-002A in C9ORF72-Associated Frontotemporal Dementia (FTD)

Frontotemporal Dementia
University of Pittsburgh
Novartis

Completed

Effect of Antacids on Gleevec® in Healthy Volunteers

Healthy

United States
Seoul National University Bundang Hospital

Recruiting

Remimazolam vs Propofol as an Induction Agent for Morbid Obesity Patients

Morbid Obesity | Desflurane | General Anesthesia | Sleeve Gastrectomy | Remimazolam

Korea, Republic of
Korea University Guro Hospital

Recruiting

Impact of CES1 Genotype on Remimazolam

Adult | Middle Aged | Elective Surgical Procedures

Korea, Republic of
Northwell Health

Terminated

Bone Wax Use for Hemostasis During Primary Unilateral Total Knee Arthroplasty

Total Knee Replacement

United States
Bausch & Lomb Incorporated

Completed

Safety and Efficacy of Bepotastine Besilate Nasal Spray in the Treatment of Seasonal Allergic Rhinitis

Seasonal Allergic Rhinitis

United States
M.D. Anderson Cancer Center
Gemin X

Terminated

Obatoclax for Systemic Mastocytosis

Leukemia | Systemic Mastocytosis

United States
Meng Li

Unknown

Safety and Efficiency Study of Pioglitazone in Combination With Imatinib Mesylate to Treat Chronic Myelogenous Leukemia (SESPI)

Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Lee's Pharmaceutical Limited

Unknown

Pazufloxacin Mesilate Ear Drops Clinical Trial Protocol

Otitis Media

China
Bausch & Lomb Incorporated

Completed

Evaluation of the Onset and Duration of Action of Bepotastine Besilate Ophthalmic Solution in Acute Allergic Conjunctivitis

Conjunctivitis, Allergic

United States
Chromaderm, Inc.

Completed

Treatment for Symptomatic Peripheral Neuropathy in Patients With Diabetes

Diabetic Neuropathies | Diabetes Mellitus, Non-Insulin-Dependent | Diabetes Mellitus, Insulin-Dependent

Canada, United States, Croatia, Finland, India, Lithuania, Netherlands, United Kingdom
Duke University
National Cancer Institute (NCI)

Completed

Imatinib Mesylate, Vatalanib, and Hydroxyurea in Treating Patients With Recurrent or Relapsed Malignant Glioma

Brain and Central Nervous System Tumors

United States
NYU Langone Health
Novartis

Terminated

Imatinib Mesylate (Gleevec) and Paclitaxel in Recurrent Patients of Ovarian and Other Cancers of Mullerian Origin

Ovarian Cancer

United States
Dongguan HEC Biopharmaceutical R&D Co., Ltd.

Recruiting

Phase 2 Study of HEC88473 Injection in Subjects With Type 2 Diabetes Mellitus

Type 2 Diabetes

China

Search clinical trials for: Enasidenib Mesylate

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in China

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations